Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 53-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 25th September 2022). On 02-OCT-2024, the patient received the 2nd dose of Shingrix. On 02-OCT-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt date: 31-MAR-2025 The patient who came to get Shingrix shots on 25th September 2022 and 2nd October 2024 (2 years apart) wanted to get a 3rd dose. The reporter consented to follow up. The lot and expiration date of 2nd dose not available during call. The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule.